The markets are likely to show some reactions to Donald Trump’s trade war, sparked by the US imposing sweeping tariffs on ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

The S&P 500 Index ($SPX) (SPY) today is up +0.29%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.12%, and the Nasdaq ...

The S&P 500 Index ($SPX) (SPY) today is up +0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.26%, and the ...

Whilst Pfizer was providing the medicines needed for the Union war effort, a young cavalry commander named Colonel Eli Lilly was serving in their army. A trained pharmaceutical chemist ...

S&P 500 E-Mini futures are up +0.05%, andMarch Nasdaq 100 E-Mini futures are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Fe ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.